Class II
Terminated
MethyLPREDNISolone Acetate Injectable Suspension USP, 400 mg/10 mL (40 mg/mL), 10 mL multi-dose vial, Rx only, MFG: Teva Pharma USA, NDC 0703-0045-01
Why: cGMP deviations: Temperature abuse
- Company
- Mckesson Medical-Surgical Inc. Corporate Office
Richmond, VA, United States - Reported
- Jun 15, 2022
- Recall started
- Apr 13, 2022
- Ended
- Nov 30, 2023
- Where sold
- USA nationwide.
- Amount
- 796 cartons/1 vial each
- Full product description
- MethyLPREDNISolone Acetate Injectable Suspension USP, 400 mg/10 mL (40 mg/mL), 10 mL multi-dose vial, Rx only, MFG: Teva Pharma USA, NDC 0703-0045-01
- Lots / codes affected
- McKesson Medical-Surgical (MMS) is not able to identify the particular lot number received by a particular consignee for the recalled prescription products. Each letter includes the date it was distributed to customers and the dates that impacted product may have been shipped to the customer.
Class I: could cause serious harm or death. Class II: could cause temporary or treatable problems. Class III: unlikely to cause harm.